Skip to main content
Fig. 5 | BMC Neurology

Fig. 5

From: Does the 5–2-1 criteria identify patients with advanced Parkinson's disease? Real-world screening accuracy and burden of 5–2-1-positive patients in 7 countries

Fig. 5

Measures of humanistic burden in 5–2-1-positive patients compared with 5–2-1-negative patients. *p < 0.0001. 5–2-1, taking ≥5 doses of oral levodopa/day, OR having ≥2 h ‘off’-time/waking day, OR having ≥1 h troublesome dyskinesia/waking day. EQ-5D, EuroQol 5-Dimension (1.0 indicates best QoL); PD, Parkinson’s disease; PDQ-39, Parkinson’s Disease Questionnaire-39 (higher score indicates worse QoL); ZBI, Zarit Burden Interview

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us